Aridis Pharmaceuticals Stock Current Ratio
Aridis Pharmaceuticals fundamentals help investors to digest information that contributes to Aridis Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Aridis Pink Sheet. The fundamental analysis module provides a way to measure Aridis Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aridis Pharmaceuticals pink sheet.
Aridis |
Aridis Pharmaceuticals Company Current Ratio Analysis
Aridis Pharmaceuticals' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Aridis Pharmaceuticals Current Ratio | 0.41 X |
Most of Aridis Pharmaceuticals' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aridis Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
CompetitionIn accordance with the recently published financial statements, Aridis Pharmaceuticals has a Current Ratio of 0.41 times. This is 85.91% lower than that of the Biotechnology sector and 94.14% lower than that of the Health Care industry. The current ratio for all United States stocks is 81.02% higher than that of the company.
Aridis Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aridis Pharmaceuticals' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Aridis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aridis Pharmaceuticals by comparing valuation metrics of similar companies.Aridis Pharmaceuticals is currently under evaluation in current ratio category among its peers.
Aridis Fundamentals
| Return On Asset | -1.08 | ||||
| Operating Margin | (9.58) % | ||||
| Current Valuation | 12.11 M | ||||
| Shares Outstanding | 36.21 M | ||||
| Shares Owned By Insiders | 31.53 % | ||||
| Shares Owned By Institutions | 11.60 % | ||||
| Number Of Shares Shorted | 2 M | ||||
| Price To Earning | (1.41) X | ||||
| Price To Book | 5.40 X | ||||
| Price To Sales | 7.33 X | ||||
| Gross Profit | (22.61 M) | ||||
| EBITDA | (29.51 M) | ||||
| Net Income | (30.37 M) | ||||
| Cash And Equivalents | 6.32 M | ||||
| Cash Per Share | 0.36 X | ||||
| Total Debt | 6.13 M | ||||
| Debt To Equity | (0.18) % | ||||
| Current Ratio | 0.41 X | ||||
| Book Value Per Share | (0.77) X | ||||
| Cash Flow From Operations | (29.13 M) | ||||
| Short Ratio | 0.22 X | ||||
| Earnings Per Share | (1.15) X | ||||
| Price To Earnings To Growth | (0.02) X | ||||
| Target Price | 10.0 | ||||
| Number Of Employees | 37 | ||||
| Beta | 0.78 | ||||
| Market Capitalization | 13.24 M | ||||
| Total Asset | 14.7 M | ||||
| Retained Earnings | (195.67 M) | ||||
| Working Capital | (25.27 M) | ||||
| Current Asset | 27.39 M | ||||
| Current Liabilities | 3.06 M | ||||
| Z Score | -26.03 | ||||
| Net Asset | 14.7 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in Aridis Pink Sheet
If you are still planning to invest in Aridis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aridis Pharmaceuticals' history and understand the potential risks before investing.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |